Abiopharma

🔍 Sabba Stephen L (Director)

Company: LIGAND PHARMACEUTICALS INC (LGND)

Report Date: 2026-06-05

Detailed Transactions and Holdings:

• Acquired 836 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 33,629.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,938 shares of Non-Qualified Stock Option (right to buy) at $237.0 per share (Derivative)
  Date: 2026-06-05 | Code: A | Expires: 2036-06-05 | equity_swap_involved: 0 | shares_owned_after: 2,938.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
• F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.